New call-to-action
New call-to-action
New call-to-action

FPWR Blog

Categories

Radius Health Adds Synthetic CBD to Development Pipeline for PWS

Radius Health has acquired a cannabidiol (CBD) compound and is preparing a PWS clinical trial using it. Radius Health believes that the drug has potential to reduce hyperphagia and improve anxiety symptoms in PWS. The news is of special interest to t...
March 9, 2021 Read More

Topics: Research

FDA requires additional trial to support NDA submission for DCCR in PWS

Soleno Therapeutics announced today that the FDA will require an additional controlled clinical trial to support an NDA submission for DCCR in PWS. This is despite pre-Covid data that showed statistically significant changes for DCCR compared to plac...
March 8, 2021 Read More

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

Saniona has received an orphan drug designation for their drug, Tesomet, for the treatment of PWS. Orphan drug designation is a special status granted by the FDA for drugs intended to treat rare diseases that affect fewer than 200,000 people in the U...
March 3, 2021 Read More

Your Child Will Be Your Hero

A special contribution by guest blogger Lindsey Larson Elliot earned the nickname “hero” before he was even born. I was 20 weeks along with our triplets, and I had noticed our only boy (Elliot) hadn’t moved in quite some time. Concerned, I called my ...
March 2, 2021 Read More

Topics: Stories of Hope

Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome

Tonix Pharmaceuticals has licensed technology using oxytocin-based therapeutics from the French National Institute of Health and Medical Research (INSERM) to treat Prader-Willi Syndrome. The co-exclusive license allows Tonix to expand its development...
February 26, 2021 Read More

Soleno Therapeutics and Vanderbilt University Announce Collaboration to Develop New K(ATP) Channel Activators

Soleno Therapeutics and Vanderbilt University announce a new collaboration which aims to discover and develop novel KATP channel activators with the potential to treat rare diseases. Soleno’s lead product candidate, DCCR, is a potent activator of KAT...
February 24, 2021 Read More

Moving Barriers for Improved Behavior in PWS [2020 CONFERENCE VIDEO]

In this 60‑minute video, Patrice Carroll, director of PWS services at Latham Centers in Massachusetts, describes what typical PWS behavior is, ways it can be improved, and how to remove barriers to allow children and adults with PWS to thrive and ach...
February 24, 2021 Read More

Topics: Research

Navigating Your Insurance Coverage with PWS [2020 CONFERENCE VIDEO]

Brian Kalasek is both a father of a young son with PWS and VP of Special Risk for Mutual of Omaha insurance company. In this 76-minute presentation, he shares successful strategies for maximizing health insurance benefits and estate planning — inform...
February 22, 2021 Read More

Topics: Research

Deconstructing Anxiety in PWS [2020 CONFERENCE VIDEO]

In this 88‑minute video, Dr. Deepan Singh discusses what anxiety looks like in PWS, what leads to it, and how can it be treated. Learn from this PWS mental health presentation, which concludes with Dr. Singh answering questions from the audience at t...
February 10, 2021 Read More

Topics: Research

About FPWR

The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).

4star120x60

NORD_MembershipLogo_Platinum_2021

excellence-in-giving-logo

Main Menu

Our Mission

The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.

Contact Us

Foundation for Prader-Willi Research
Phone: 888-322-5487
Email: info@fpwr.org

FPWR
440 N Barranca Ave #3620
Covina, CA 91723

Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.